Tuesday, August 29, 2017

Calimmune Acquired By CSL Behring For $91M

Tucson-based Calimmune, a biotechnology company focused on stem cell therapy, has been acquired by CSL Behring, CSL said on Monday, in a deal worth $91M up front, but worth up to $400M in earn out. Calimmune's founder is from the University of Arizona, and the company received early seed funding from the Desert Angels. Calimmune's lead product is CAL-H, an HSC gene therapy for the treatment of sickle cell disease. CSL said that the deal has potential, performance based milestones of up to $325M over a period of eight years.